Maternal Serum Screen, Alpha Fetoprotein

Also known as: MS AFP

Clinical Use

Use

The Maternal Serum Screen, Alpha Fetoprotein (MS AFP) is a second-trimester screening test used to assess the risk of open neural tube defects, such as spina bifida, in the fetus. It is recommended for pregnant female patients during the specified gestational period. This test provides critical information to guide further diagnostic procedures and ensure proper prenatal care for patients at risk.

Special Instructions

Not provided.

Limitations

This screening cannot confirm open neural tube defects on its own. Factors such as gestational age accuracy, multiple gestations, ventral wall defects, or fetal demise might influence results. Genetic counseling and further diagnostic imaging or procedures (like amniocentesis) may be necessary to confirm findings and provide appropriate patient guidance.

Test Details

New York Approved

Methodology

Immunoassay (CLIA)

Biomarkers

Alpha Fetoprotein

Analyte

Patient's AFP

Concentration / Level • Quantitative (Continuous) (e.g., copies/mL, % expression)

MoM for AFP

Concentration / Level • Quantitative (Continuous) (e.g., copies/mL, % expression)

LOINC Codes

Result Codes

1834-1 - AFP SerPl-mCnc
11778-8 - Deliv date Clin est
20450-3 - AFP MoM SerPl
49586-1 - Integrated scn Patient-Imp
19151-0 - Specimen drawn SerPl
21299-3 - GA method
44877-9 - IDDM Patient Ql
8670-2 - Family member diseases Hx
21484-1 - Mother's race
11878-6 - # Fetuses US
21612-7 - Age - Reported
64234-8 - Current smoker
18185-9 - GA
29463-7 - Weight

Result Turnaround Time

2-3 days

Specimen

Serum

Volume

1 mL

Minimum Volume

0.5 mL

Container

Serum Separator Tube (SST) or Plain Red.

Collection Instructions

Specimen must be drawn between 14 weeks, 0 days and 24 weeks, 6 days gestation. Separate from cells as soon as possible or within 2 hours of collection.